PMID- 25169472
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20211203
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 15
IP  - 16
DP  - 2014
TI  - The mTOR signalling pathway in cancer and the potential mTOR inhibitory 
      activities of natural phytochemicals.
PG  - 6463-75
AB  - The mammalian target of rapamycin (mTOR) kinase plays an important role in 
      regulating cell growth and cell cycle progression in response to cellular 
      signals. It is a key regulator of cell proliferation and many upstream activators 
      and downstream effectors of mTOR are known to be deregulated in various types of 
      cancers. Since the mTOR signalling pathway is commonly activated in human 
      cancers, many researchers are actively developing inhibitors that target key 
      components in the pathway and some of these drugs are already on the market. 
      Numerous preclinical investigations have also suggested that some herbs and 
      natural phytochemicals, such as curcumin, resveratrol, timosaponin III, gallic 
      acid, diosgenin, pomegranate, epigallocatechin gallate (EGCC), genistein and 
      3,3'-diindolylmethane inhibit the mTOR pathway either directly or indirectly. 
      Some of these natural compounds are also in the clinical trial stage. In this 
      review, the potential anti-cancer and chemopreventive activities and the current 
      status of clinical trials of these phytochemicals are discussed.
FAU - Tan, Heng Kean
AU  - Tan HK
AD  - Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, 
      Technology and Innovation (MOSTI), Halaman Bukit Gambir, Malaysia E-mail : 
      tanml@usm.my, drtanmelan@yahoo.com.
FAU - Moad, Ahmed Ismail Hassan
AU  - Moad AI
FAU - Tan, Mei Lan
AU  - Tan ML
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Phytochemicals)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Cell Cycle
MH  - Cell Proliferation
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mechanistic Target of Rapamycin Complex 2
MH  - Multiprotein Complexes/antagonists & inhibitors
MH  - Neoplasms/*drug therapy
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Phytochemicals/*pharmacology/therapeutic use
MH  - *Phytotherapy
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/metabolism
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
EDAT- 2014/08/30 06:00
MHDA- 2015/06/09 06:00
CRDT- 2014/08/30 06:00
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
AID - 10.7314/apjcp.2014.15.16.6463 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2014;15(16):6463-75. doi: 10.7314/apjcp.2014.15.16.6463.